Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 06 04:00PM ET
16.99
Dollar change
+0.53
Percentage change
3.23
%
Index- P/E- EPS (ttm)-8.92 Insider Own30.01% Shs Outstand5.48M Perf Week5.59%
Market Cap107.89M Forward P/E- EPS next Y-7.45 Insider Trans-0.04% Shs Float4.44M Perf Month34.63%
Income-45.61M PEG- EPS next Q-2.36 Inst Own18.52% Short Float0.23% Perf Quarter10.25%
Sales21.48M P/S5.02 EPS this Y41.70% Inst Trans-23.96% Short Ratio0.69 Perf Half Y27.86%
Book/sh5.47 P/B3.11 EPS next Y4.55% ROA-50.15% Short Interest0.01M Perf Year54.47%
Cash/sh17.20 P/C0.99 EPS next 5Y17.00% ROE-101.78% 52W Range7.69 - 20.04 Perf YTD72.64%
Dividend Est.- P/FCF4.48 EPS past 5Y22.47% ROI-129.82% 52W High-15.22% Beta0.63
Dividend TTM- Quick Ratio2.74 Sales past 5Y42.26% Gross Margin98.77% 52W Low120.88% ATR (14)0.97
Dividend Ex-Date- Current Ratio2.74 EPS Y/Y TTM54.42% Oper. Margin-235.24% RSI (14)64.39 Volatility6.25% 6.87%
Employees65 Debt/Eq0.05 Sales Y/Y TTM-100.00% Profit Margin-212.33% Recom2.00 Target Price36.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q49.06% Payout- Rel Volume1.67 Prev Close16.46
Sales Surprise42.22% EPS Surprise11.21% Sales Q/Q- EarningsAug 08 AMC Avg Volume14.95K Price16.99
SMA2013.30% SMA5016.79% SMA20033.03% Trades Volume25,000 Change3.23%
Date Action Analyst Rating Change Price Target Change
Sep-13-21Initiated H.C. Wainwright Neutral $3.50
Sep-02-21Downgrade William Blair Outperform → Mkt Perform
Mar-23-21Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-20Downgrade Jefferies Buy → Hold $30 → $10
Oct-19-20Initiated Truist Buy $55
Oct-16-19Initiated Mizuho Buy $20
Nov-19-18Initiated Leerink Partners Outperform $45
Oct-08-18Upgrade B. Riley FBR Neutral → Buy $42
Aug-08-18Initiated Robert W. Baird Outperform $74
Apr-13-18Downgrade Chardan Capital Markets Buy → Neutral $35 → $50
Aug-08-24 05:22PM
04:05PM
Jul-15-24 08:00AM
Jun-18-24 08:00AM
Jun-17-24 08:00AM
08:00AM Loading…
Jun-10-24 08:00AM
Jun-05-24 08:00AM
May-22-24 08:00AM
May-13-24 08:53AM
May-09-24 05:04AM
May-08-24 04:05PM
Mar-28-24 10:53PM
04:05PM
Mar-25-24 12:52PM
Feb-08-24 08:00AM
08:00AM Loading…
Jan-04-24 08:00AM
Nov-10-23 04:05PM
08:00AM
Nov-08-23 05:08PM
04:05PM
08:00AM
Oct-17-23 10:59AM
07:00AM
Oct-11-23 08:00AM
Oct-02-23 08:00AM
Sep-19-23 04:05PM
Aug-09-23 06:11PM
04:05PM
Jul-17-23 08:00AM
Jun-21-23 08:00AM
08:00AM Loading…
Jun-07-23 08:00AM
May-23-23 04:05PM
May-04-23 06:28PM
04:05PM
Apr-18-23 08:00AM
Mar-30-23 10:04AM
Mar-22-23 04:05PM
Feb-15-23 08:00AM
Dec-19-22 03:19PM
08:00AM
Nov-14-22 08:00AM
Nov-09-22 09:35AM
Nov-08-22 04:05PM
Nov-04-22 08:00AM
Oct-24-22 08:00AM
Oct-21-22 09:36AM
Oct-05-22 04:05PM
Aug-24-22 08:00AM
Aug-09-22 04:05PM
Aug-04-22 12:00PM
10:00AM
06:27AM
Jul-21-22 07:22AM
06:26AM
Jul-20-22 05:48PM
04:05PM
Jun-22-22 08:00AM
07:00AM
Jun-21-22 08:00AM
Jun-08-22 08:00AM
07:58AM
Jun-06-22 08:00AM
Jun-03-22 04:05PM
May-27-22 09:38AM
May-25-22 11:06AM
May-12-22 04:05PM
Apr-01-22 05:00PM
Mar-23-22 04:19PM
Mar-21-22 08:00AM
Mar-10-22 04:05PM
Feb-09-22 08:00AM
Jan-19-22 09:38PM
Jan-07-22 05:00PM
Jan-06-22 08:00AM
Jan-04-22 08:00AM
Dec-07-21 10:00AM
Dec-03-21 05:00PM
Nov-12-21 08:00AM
Nov-04-21 04:05PM
Nov-01-21 10:32AM
Oct-19-21 07:30AM
Oct-06-21 08:00AM
Oct-01-21 06:04PM
Sep-24-21 06:35AM
Sep-02-21 03:18PM
12:05PM
10:17AM
06:49AM
Sep-01-21 04:02PM
Aug-18-21 08:00AM
Aug-05-21 05:45PM
04:01PM
Aug-03-21 08:00AM
Jul-28-21 03:03PM
Jul-20-21 08:00AM
Jul-02-21 05:00PM
Jun-26-21 03:26AM
Jun-23-21 08:00AM
Jun-09-21 08:00AM
Jun-04-21 05:00PM
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
White Nicole SChief Manufacturing OfficerAug 02 '24Sale14.2378511,17312,068Aug 05 04:10 PM
Okazaki Jason ACEO and PresidentAug 02 '24Sale14.2398113,96215,101Aug 05 04:05 PM
Schornstein Alexander10% OwnerJul 03 '24Buy12.294,56256,067688,675Jul 08 10:48 AM
Schornstein Alexander10% OwnerJul 05 '24Buy12.524,43855,564693,113Jul 08 10:48 AM
Bjorkquist Jeanette MPrincipal Accounting OfficerMay 23 '24Sale14.93243583,142May 24 04:10 PM
McHutchison John GDirectorMay 23 '24Sale14.932,11731,61519,104May 24 04:10 PM
White Nicole SChief Manufacturing OfficerMay 23 '24Sale14.931722,56912,853May 24 04:05 PM
Okazaki Jason ACEO and PresidentMay 23 '24Sale14.935498,19916,082May 24 04:05 PM
White Nicole SChief Manufacturing OfficerApr 30 '24Sale12.711,25515,94713,025May 01 04:10 PM
Okazaki Jason ACEO and PresidentApr 30 '24Sale12.711,56919,93716,423May 01 04:05 PM
McHutchison John GDirectorApr 01 '24Sale13.071,20615,76521,221Apr 02 04:25 PM
Bjorkquist Jeanette MPrincipal Accounting OfficerApr 01 '24Sale13.071141,4903,166Apr 02 04:20 PM
White Nicole SChief Manufacturing OfficerApr 01 '24Sale13.071972,57510,947Apr 02 04:15 PM
Okazaki Jason ACEO and PresidentApr 01 '24Sale13.073544,62713,826Apr 02 04:05 PM
Okazaki Jason ACEO and PresidentMar 27 '24Sale12.873925,04514,180Mar 29 04:05 PM
Schornstein Alexander10% OwnerJan 18 '24Buy0.80345,086276,0698,209,372Jan 19 11:01 AM
Schornstein Alexander10% OwnerJan 17 '24Buy0.78299,994235,1957,864,286Jan 19 11:01 AM
Schornstein Alexander10% OwnerNov 20 '23Buy0.72300,000215,4007,464,292Nov 22 04:10 PM
Schornstein Alexander10% OwnerNov 21 '23Buy0.67100,00066,7007,564,292Nov 22 04:10 PM
White Nicole SChief Manufacturing OfficerNov 17 '23Sale0.6947732993,774Nov 21 04:05 PM
White Nicole SChief Manufacturing OfficerOct 03 '23Sale0.801,8911,50494,251Oct 04 04:15 PM
Delaney William E IVChief Scientific OfficerOct 03 '23Sale0.801,8911,504150,853Oct 04 04:10 PM
Okazaki Jason ACEO and PresidentOct 03 '23Sale0.802,3631,879174,923Oct 04 04:05 PM
Last Close
Sep 06 04:00PM ET
0.8131
Dollar change
+0.0399
Percentage change
5.16
%
XLO Xilio Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-2.11 Insider Own46.40% Shs Outstand27.61M Perf Week1.18%
Market Cap35.74M Forward P/E- EPS next Y-0.58 Insider Trans2.44% Shs Float23.56M Perf Month-5.62%
Income-65.53M PEG- EPS next Q-0.25 Inst Own15.15% Short Float0.47% Perf Quarter-20.28%
Sales2.36M P/S15.14 EPS this Y54.80% Inst Trans-3.75% Short Ratio0.47 Perf Half Y1.76%
Book/sh0.76 P/B1.07 EPS next Y54.11% ROA-71.92% Short Interest0.11M Perf Year-71.96%
Cash/sh1.71 P/C0.48 EPS next 5Y- ROE-130.03% 52W Range0.49 - 2.90 Perf YTD47.84%
Dividend Est.- P/FCF- EPS past 5Y-44.91% ROI-159.90% 52W High-71.96% Beta-0.05
Dividend TTM- Quick Ratio2.02 Sales past 5Y0.00% Gross Margin23.76% 52W Low65.94% ATR (14)0.09
Dividend Ex-Date- Current Ratio2.02 EPS Y/Y TTM31.42% Oper. Margin-2830.04% RSI (14)44.89 Volatility15.82% 10.74%
Employees73 Debt/Eq0.26 Sales Y/Y TTM- Profit Margin-2780.27% Recom1.33 Target Price5.50
Option/ShortNo / Yes LT Debt/Eq0.23 EPS Q/Q65.78% Payout- Rel Volume0.70 Prev Close0.77
Sales Surprise-92.14% EPS Surprise-4.35% Sales Q/Q- EarningsAug 08 BMO Avg Volume236.61K Price0.81
SMA20-4.38% SMA50-10.64% SMA200-9.42% Trades Volume164,736 Change5.16%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Aug-28-24 04:01PM
Aug-08-24 07:30AM
Jun-13-24 04:05PM
May-29-24 06:05AM
May-14-24 01:54PM
07:30AM Loading…
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
07:30AM Loading…
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
07:30AM Loading…
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08 '24Sale0.647334692,019,563Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08 '24Sale0.64267171734,546Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11 '24Sale0.871,5661,3622,021,836Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12 '24Sale0.831,5401,2782,020,296Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11 '24Sale0.87569495735,373Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12 '24Sale0.83560465734,813Jan 16 06:16 PM
Last Close
Sep 06 04:00PM ET
7.34
Dollar change
-0.24
Percentage change
-3.17
%
KYTX Kyverna Therapeutics Inc. daily Stock Chart
IndexRUT P/E- EPS (ttm)-2.63 Insider Own59.07% Shs Outstand43.12M Perf Week-8.48%
Market Cap316.72M Forward P/E- EPS next Y-4.00 Insider Trans0.00% Shs Float17.66M Perf Month5.16%
Income-91.63M PEG- EPS next Q-0.76 Inst Own37.39% Short Float16.61% Perf Quarter-45.79%
Sales0.00M P/S- EPS this Y96.28% Inst Trans- Short Ratio4.73 Perf Half Y-74.50%
Book/sh7.73 P/B0.95 EPS next Y-19.95% ROA- Short Interest2.93M Perf Year-
Cash/sh8.02 P/C0.91 EPS next 5Y- ROE- 52W Range6.30 - 35.06 Perf YTD-75.53%
Dividend Est.- P/FCF- EPS past 5Y- ROI-26.98% 52W High-79.06% Beta-
Dividend TTM- Quick Ratio14.86 Sales past 5Y-37.90% Gross Margin- 52W Low16.51% ATR (14)0.70
Dividend Ex-Date- Current Ratio14.86 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)44.01 Volatility8.04% 8.56%
Employees96 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price41.25
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-119.89% Payout- Rel Volume0.23 Prev Close7.58
Sales Surprise- EPS Surprise4.05% Sales Q/Q- EarningsAug 12 AMC Avg Volume620.17K Price7.34
SMA20-1.37% SMA50-9.83% SMA200-54.20% Trades Volume143,706 Change-3.17%
Date Action Analyst Rating Change Price Target Change
Jul-03-24Initiated H.C. Wainwright Neutral $8
Mar-04-24Initiated Wells Fargo Overweight $44
Mar-04-24Initiated Morgan Stanley Overweight $40
Mar-04-24Initiated Leerink Partners Outperform $48
Mar-04-24Initiated JP Morgan Overweight $39
Aug-21-24 04:05PM
Aug-12-24 04:08PM
04:05PM
Jul-16-24 11:33AM
08:52AM
04:05PM Loading…
Jul-15-24 04:05PM
Jun-20-24 08:55AM
Jun-17-24 04:05PM
Jun-10-24 04:05PM
Jun-07-24 08:55AM
May-14-24 10:54PM
04:05PM
Apr-11-24 05:01PM
Mar-29-24 02:59PM
Mar-26-24 04:05PM
07:00AM Loading…
Mar-14-24 07:00AM
Mar-07-24 07:26PM
06:14PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Karen MarieChief Technology OfficerJun 06 '24Option Exercise4.429,63642,5919,636Jun 10 06:56 PM
Jones Ryan AlexanderChief Financial OfficerMay 28 '24Option Exercise0.7318,01613,15243,950May 29 04:33 PM
Vida Ventures, LLC10% OwnerFeb 12 '24Buy22.00253,1365,568,992252,553Feb 14 07:04 PM
Bain Capital Life Sciences Inv10% OwnerFeb 12 '24Buy22.00450,0009,900,0003,163,868Feb 14 05:26 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
Northpond Ventures III GP, LLCFormer 10% OwnerFeb 12 '24Buy22.00450,0009,900,000450,000Feb 12 05:51 PM
Last Close
Sep 06 04:00PM ET
15.72
Dollar change
-0.43
Percentage change
-2.66
%
RCUS Arcus Biosciences Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-3.10 Insider Own46.96% Shs Outstand75.50M Perf Week-9.29%
Market Cap1.44B Forward P/E- EPS next Y-4.63 Insider Trans-0.06% Shs Float48.50M Perf Month12.29%
Income-249.00M PEG- EPS next Q-1.00 Inst Own54.17% Short Float14.37% Perf Quarter-1.13%
Sales247.00M P/S5.82 EPS this Y24.38% Inst Trans-0.66% Short Ratio10.13 Perf Half Y-12.28%
Book/sh6.96 P/B2.26 EPS next Y-47.40% ROA-20.70% Short Interest6.97M Perf Year-30.13%
Cash/sh10.60 P/C1.48 EPS next 5Y7.80% ROE-41.47% 52W Range12.95 - 22.68 Perf YTD-17.70%
Dividend Est.- P/FCF- EPS past 5Y-23.70% ROI-39.21% 52W High-30.69% Beta0.90
Dividend TTM- Quick Ratio5.14 Sales past 5Y164.80% Gross Margin94.74% 52W Low21.39% ATR (14)0.92
Dividend Ex-Date- Current Ratio5.14 EPS Y/Y TTM21.51% Oper. Margin-110.53% RSI (14)44.56 Volatility5.47% 5.83%
Employees577 Debt/Eq0.02 Sales Y/Y TTM103.73% Profit Margin-100.81% Recom1.50 Target Price33.12
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q0.36% Payout- Rel Volume0.53 Prev Close16.15
Sales Surprise48.65% EPS Surprise8.52% Sales Q/Q34.48% EarningsAug 08 AMC Avg Volume688.38K Price15.72
SMA20-4.84% SMA501.08% SMA200-4.05% Trades Volume365,217 Change-2.66%
Date Action Analyst Rating Change Price Target Change
Nov-18-22Initiated BofA Securities Neutral $33
Oct-11-22Initiated Morgan Stanley Overweight $40
Oct-15-21Resumed BTIG Research Buy $57
Nov-24-20Initiated Berenberg Buy $50
Nov-23-20Initiated Evercore ISI Outperform
Apr-03-20Initiated Cantor Fitzgerald Overweight $21
Mar-04-20Initiated Barclays Overweight $24
Nov-12-19Initiated SunTrust Buy $20
Sep-27-19Initiated Mizuho Buy $22
May-24-19Resumed Citigroup Buy $25
Aug-28-24 02:33PM
Aug-27-24 04:05PM
Aug-26-24 04:35PM
Aug-21-24 04:05PM
Aug-16-24 04:52AM
06:15PM Loading…
Aug-08-24 06:15PM
04:05PM
Aug-01-24 10:01AM
08:00AM
Jul-25-24 04:05PM
Jul-09-24 04:35PM
06:32AM
Jul-08-24 06:00PM
Jun-25-24 04:35PM
Jun-11-24 04:35PM
08:30AM Loading…
Jun-10-24 08:30AM
Jun-07-24 10:55AM
Jun-06-24 04:05PM
Jun-02-24 08:00AM
Jun-01-24 08:00AM
May-24-24 04:35PM
May-10-24 01:38PM
May-09-24 04:35PM
03:48PM
03:47AM
May-08-24 09:59PM
05:45PM
04:02PM
May-02-24 04:05PM
May-01-24 10:01AM
04:00PM Loading…
Apr-24-24 04:00PM
Apr-23-24 04:05PM
Apr-09-24 04:35PM
Mar-29-24 07:01PM
Mar-26-24 04:35PM
Mar-20-24 07:00PM
Mar-11-24 04:35PM
Feb-29-24 03:14AM
Feb-28-24 04:05PM
Feb-27-24 04:35PM
Feb-22-24 11:10AM
09:55AM
07:16AM
Feb-21-24 04:37PM
04:05PM
Feb-09-24 04:35PM
Feb-07-24 05:00PM
Feb-05-24 12:59PM
Jan-29-24 05:00PM
Jan-26-24 04:35PM
Jan-16-24 05:00PM
Dec-11-23 04:35PM
Dec-04-23 08:00AM
Nov-27-23 04:35PM
Nov-14-23 04:00PM
Nov-13-23 04:35PM
Nov-08-23 04:05PM
Nov-07-23 04:01PM
Nov-06-23 05:00PM
Oct-31-23 10:01AM
Oct-24-23 04:35PM
Oct-17-23 04:00PM
Oct-10-23 04:35PM
Sep-27-23 05:14AM
Sep-26-23 04:35PM
Sep-11-23 04:35PM
Sep-05-23 07:37PM
Aug-24-23 04:35PM
11:30AM
09:02AM
Aug-23-23 11:39AM
09:00AM
Aug-09-23 04:35PM
Aug-07-23 09:15AM
08:00AM
Aug-03-23 05:55PM
Aug-02-23 05:25PM
Aug-01-23 05:45PM
Jul-25-23 04:35PM
Jul-11-23 04:35PM
Jul-03-23 06:50AM
Jun-26-23 04:35PM
Jun-21-23 08:00PM
Jun-12-23 12:08PM
Jun-09-23 04:35PM
Jun-05-23 02:59PM
Jun-03-23 01:30PM
May-30-23 04:00PM
May-26-23 04:05PM
10:27AM
May-24-23 04:35PM
May-17-23 08:30AM
May-16-23 11:51AM
09:31AM
May-15-23 08:30AM
May-11-23 09:44AM
09:33AM
07:44AM
May-09-23 06:15PM
04:05PM
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Azoy AlexanderChief Accounting OfficerAug 13 '24Sale14.971,35720,31419,070Aug 15 04:45 PM
Jarrett JenniferChief Operating OfficerMar 27 '24Sale17.5511,551202,720215,253Mar 29 04:20 PM
Jarrett JenniferChief Operating OfficerMar 18 '24Sale17.9213,449240,941226,804Mar 20 04:19 PM
Jarrett JenniferChief Operating OfficerFeb 27 '24Sale20.1134,070685,148240,253Feb 28 07:55 PM
Jarrett JenniferChief Operating OfficerFeb 26 '24Sale20.0724,555492,819274,323Feb 28 07:55 PM
Jaen Juan C.PresidentFeb 27 '24Sale20.1023,132464,9531,188,233Feb 28 07:55 PM
Jaen Juan C.PresidentFeb 26 '24Sale20.063,90078,2341,211,365Feb 28 07:55 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Goeltz II Robert C.Chief Financial OfficerJan 02 '24Sale20.002,00440,08051,831Jan 04 05:23 PM
Jaen Juan C.PresidentJan 02 '24Sale20.096,975140,1281,215,265Jan 04 05:22 PM
Jarrett JenniferChief Operating OfficerDec 22 '23Sale17.7621,521382,213258,878Dec 26 04:04 PM
Azoy AlexanderChief Accounting OfficerDec 01 '23Sale14.952824,21611,596Dec 05 04:28 PM
Jarrett JenniferChief Operating OfficerSep 22 '23Sale19.9921,369427,166302,691Sep 26 04:35 PM
Last Close
Sep 06 04:00PM ET
0.7642
Dollar change
+0.0028
Percentage change
0.37
%
ALVR AlloVir Inc daily Stock Chart
Index- P/E- EPS (ttm)-1.23 Insider Own49.77% Shs Outstand113.97M Perf Week-1.33%
Market Cap88.16M Forward P/E- EPS next Y-0.29 Insider Trans-0.18% Shs Float57.95M Perf Month5.84%
Income-140.34M PEG- EPS next Q-0.10 Inst Own40.51% Short Float9.57% Perf Quarter-1.04%
Sales0.00M P/S- EPS this Y72.86% Inst Trans24.76% Short Ratio17.05 Perf Half Y3.72%
Book/sh1.04 P/B0.73 EPS next Y41.61% ROA-67.85% Short Interest5.55M Perf Year-74.78%
Cash/sh1.12 P/C0.68 EPS next 5Y29.50% ROE-80.33% 52W Range0.58 - 3.13 Perf YTD12.42%
Dividend Est.- P/FCF- EPS past 5Y-70.96% ROI-109.11% 52W High-75.58% Beta0.76
Dividend TTM- Quick Ratio55.08 Sales past 5Y-37.09% Gross Margin- 52W Low31.76% ATR (14)0.03
Dividend Ex-Date- Current Ratio55.08 EPS Y/Y TTM32.62% Oper. Margin0.00% RSI (14)51.29 Volatility3.46% 4.29%
Employees112 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom4.00 Target Price0.80
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q88.96% Payout- Rel Volume0.09 Prev Close0.76
Sales Surprise- EPS Surprise51.50% Sales Q/Q- EarningsAug 01 Avg Volume325.21K Price0.76
SMA201.41% SMA500.85% SMA200-14.64% Trades Volume27,670 Change0.37%
Date Action Analyst Rating Change Price Target Change
Dec-26-23Downgrade BofA Securities Buy → Underperform $17 → $1
Dec-22-23Downgrade Piper Sandler Overweight → Neutral
Dec-22-23Downgrade Leerink Partners Outperform → Market Perform
Dec-22-23Downgrade JP Morgan Overweight → Underweight
Aug-18-23Initiated BofA Securities Buy $17
Oct-19-21Resumed Morgan Stanley Overweight $48
Aug-24-20Initiated SVB Leerink Outperform $41
Aug-24-20Initiated Morgan Stanley Overweight $49
Aug-24-20Initiated JP Morgan Overweight $50
Aug-09-24 02:52PM
May-14-24 08:53AM
Mar-18-24 03:53PM
Mar-13-24 11:53AM
10:00AM
05:50AM Loading…
Mar-12-24 05:50AM
Mar-06-24 06:17PM
Mar-04-24 05:37PM
Feb-28-24 01:06AM
Feb-27-24 08:00AM
Feb-26-24 12:27PM
Feb-23-24 10:30AM
Jan-29-24 09:40AM
Jan-24-24 09:45AM
Jan-12-24 09:35AM
11:03AM Loading…
Jan-05-24 11:03AM
08:37AM
Dec-26-23 10:04AM
Dec-22-23 09:31AM
08:30AM
07:10AM
07:00AM
Dec-05-23 08:55AM
Nov-16-23 07:00AM
Nov-02-23 10:04AM
07:00AM
Sep-21-23 02:44PM
Sep-14-23 09:59AM
Aug-28-23 07:00AM
Aug-03-23 07:00AM
07:17AM Loading…
Jul-21-23 07:17AM
Jul-12-23 03:12AM
Jul-04-23 07:34AM
Jul-03-23 03:59AM
Jun-27-23 12:00PM
Jun-23-23 01:56PM
Jun-21-23 09:20PM
04:18PM
Jun-09-23 11:04AM
Jun-05-23 07:00AM
May-16-23 07:00AM
May-04-23 07:00AM
May-01-23 07:00AM
Apr-26-23 05:12PM
07:00AM
Mar-30-23 11:12AM
Feb-23-23 04:15PM
Feb-15-23 10:05AM
07:07AM
07:00AM
Feb-10-23 09:55AM
Feb-07-23 10:17AM
Feb-01-23 07:00AM
Jan-25-23 12:00PM
09:55AM
09:40AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-10-22 05:15PM
Nov-15-22 07:00AM
Nov-03-22 09:07AM
07:00AM
Oct-21-22 08:30AM
Sep-06-22 09:55AM
Aug-31-22 07:00AM
Aug-19-22 09:55AM
Aug-04-22 07:00AM
Aug-03-22 09:55AM
Aug-01-22 08:09AM
Jul-27-22 07:00AM
Jun-07-22 12:07PM
08:30AM
May-05-22 07:00AM
Apr-21-22 11:35AM
Apr-20-22 07:00AM
Apr-04-22 07:40PM
Mar-31-22 07:00AM
Mar-23-22 09:56AM
Mar-22-22 07:00AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Jan-05-22 07:30AM
Jan-03-22 04:05PM
Dec-16-21 04:05PM
Dec-11-21 01:00PM
Nov-17-21 11:57AM
Nov-15-21 07:00AM
Nov-10-21 11:48AM
Nov-05-21 07:00AM
Oct-29-21 09:47AM
Oct-06-21 11:31AM
Oct-05-21 06:48AM
Oct-04-21 07:00AM
Sep-29-21 02:09PM
07:00AM
Sep-07-21 07:00AM
Sep-03-21 08:19AM
Aug-26-21 01:41PM
Aug-06-21 07:00AM
Jun-27-21 03:19AM
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brainard DianaChief Executive OfficerAug 20 '24Sale0.745,3903,996753,923Aug 22 04:15 PM
Brainard DianaOfficerAug 20 '24Proposed Sale0.745,3903,996Aug 21 11:14 AM
Miller EdwardGeneral CounselAug 19 '24Sale0.76422321215,981Aug 20 04:15 PM
Sinha VikasSee RemarksAug 19 '24Sale0.763,1592,3991,153,584Aug 20 04:15 PM
Hagen Brett RChief Accounting OfficerAug 19 '24Sale0.7654441371,981Aug 20 04:15 PM
Brainard DianaChief Executive OfficerAug 19 '24Sale0.763,0912,348759,313Aug 20 04:15 PM
Sinha VikasOwnerAug 19 '24Proposed Sale0.763,1592,399Aug 19 08:00 PM
Brainard DianaOfficerAug 19 '24Proposed Sale0.763,0912,348Aug 19 08:00 PM
Hagen Brett ROfficerAug 19 '24Proposed Sale0.76544413Aug 19 08:00 PM
Miller EdwardOfficerAug 19 '24Proposed Sale0.76422321Aug 19 08:00 PM
Miller EdwardGeneral CounselAug 05 '24Sale0.732,3231,707216,403Aug 07 04:15 PM
Brainard DianaChief Executive OfficerAug 05 '24Sale0.7310,8477,970762,404Aug 07 04:15 PM
Sinha VikasSee RemarksAug 05 '24Sale0.735,2513,8581,156,743Aug 07 04:15 PM
Hagen Brett RChief Accounting OfficerAug 05 '24Sale0.731,6921,24372,525Aug 07 04:15 PM
Brainard DianaOfficerAug 05 '24Proposed Sale0.7310,8477,970Aug 06 08:00 PM
Sinha VikasOwnerAug 05 '24Proposed Sale0.735,2513,858Aug 06 08:00 PM
Hagen Brett ROfficerAug 05 '24Proposed Sale0.731,6921,243Aug 06 08:00 PM
Miller EdwardOfficerAug 05 '24Proposed Sale0.732,3231,707Aug 06 08:00 PM
Hagen Brett RChief Accounting OfficerJul 19 '24Sale0.7547935974,698Jul 23 04:28 PM
Hagen Brett RChief Accounting OfficerJul 22 '24Sale0.7448135674,217Jul 23 04:28 PM
Brainard DianaChief Executive OfficerJul 19 '24Sale0.759,7317,299773,251Jul 23 04:28 PM
Sinha VikasSee RemarksJul 22 '24Sale0.741,8581,3731,161,994Jul 23 04:27 PM
Sinha VikasSee RemarksJul 19 '24Sale0.751,5421,1571,163,852Jul 23 04:27 PM
Miller EdwardGeneral CounselJul 22 '24Sale0.74757560218,726Jul 23 04:25 PM
Miller EdwardGeneral CounselJul 19 '24Sale0.75634476219,483Jul 23 04:25 PM
Miller EdwardGeneral CounselJul 02 '24Sale0.72379273220,117Jul 03 04:14 PM
Sinha VikasSee RemarksJul 02 '24Sale0.729396761,165,394Jul 03 04:14 PM
Hagen Brett RChief Accounting OfficerJul 02 '24Sale0.7230421975,177Jul 03 04:12 PM
Brainard DianaChief Executive OfficerJul 02 '24Sale0.721,4891,072782,982Jul 03 04:11 PM
Brainard DianaChief Executive OfficerMay 21 '24Sale0.795,1494,080784,471May 23 05:24 PM
Hagen Brett RChief Accounting OfficerMay 17 '24Sale0.7554140575,481May 21 04:35 PM
Brainard DianaChief Executive OfficerMay 17 '24Sale0.753,0752,304789,620May 21 04:35 PM
Sinha VikasSee RemarksMay 17 '24Sale0.753,1432,3551,129,996May 21 04:33 PM
Miller EdwardGeneral CounselMay 17 '24Sale0.75420315220,496May 21 04:33 PM
Brainard DianaChief Executive OfficerMay 03 '24Sale0.8010,2408,151792,695May 07 04:15 PM
Hagen Brett RChief Accounting OfficerMay 03 '24Sale0.801,5971,27176,022May 07 04:15 PM
Sinha VikasSee RemarksMay 03 '24Sale0.804,9573,9461,133,139May 07 04:15 PM
Miller EdwardGeneral CounselMay 03 '24Sale0.802,3111,840220,916May 07 04:15 PM
Hagen Brett RChief Accounting OfficerApr 22 '24Sale0.7548036077,619Apr 23 04:15 PM
Hagen Brett RChief Accounting OfficerApr 19 '24Sale0.7547335578,099Apr 23 04:15 PM
Miller EdwardGeneral CounselApr 22 '24Sale0.75757568223,227Apr 23 04:15 PM
Miller EdwardGeneral CounselApr 19 '24Sale0.75626470223,984Apr 23 04:15 PM
Brainard DianaChief Executive OfficerApr 19 '24Sale0.759,6017,207802,935Apr 23 04:15 PM
Sinha VikasSee RemarksApr 22 '24Sale0.751,8571,3931,138,096Apr 23 04:15 PM
Sinha VikasSee RemarksApr 19 '24Sale0.751,5211,1421,139,953Apr 23 04:15 PM
Miller EdwardGeneral CounselApr 02 '24Sale0.77368284224,610Apr 04 04:15 PM
Brainard DianaChief Executive OfficerApr 02 '24Sale0.771,5331,183812,536Apr 04 04:15 PM
Hagen Brett RChief Accounting OfficerApr 02 '24Sale0.7728121778,572Apr 04 04:15 PM
Sinha VikasSee RemarksApr 02 '24Sale0.778856831,141,474Apr 04 04:15 PM
Brainard DianaChief Executive OfficerFeb 21 '24Sale0.715,1553,650814,069Feb 22 04:18 PM
Brainard DianaChief Executive OfficerFeb 20 '24Sale0.703,0972,153819,224Feb 22 04:18 PM
Miller EdwardGeneral CounselFeb 20 '24Sale0.70385268224,978Feb 22 04:16 PM
Sinha VikasSee RemarksFeb 20 '24Sale0.702,8932,0111,142,359Feb 22 04:15 PM
Hagen Brett RChief Accounting OfficerFeb 20 '24Sale0.7049434378,853Feb 22 04:15 PM
Hagen Brett RChief Accounting OfficerFeb 08 '24Sale0.6711,1507,49479,347Feb 09 08:01 PM
Sinha VikasSee RemarksFeb 05 '24Sale0.6718,33112,2821,145,252Feb 06 04:46 PM
Miller EdwardGeneral CounselFeb 05 '24Sale0.678,8695,942225,363Feb 06 04:40 PM
Hagen Brett RChief Accounting OfficerFeb 05 '24Sale0.675,7923,88190,497Feb 06 04:39 PM
Brainard DianaChief Executive OfficerFeb 05 '24Sale0.6741,42127,752822,321Feb 06 04:38 PM
Sinha VikasSee RemarksJan 23 '24Sale0.673,2052,1501,163,583Jan 25 04:15 PM
Brainard DianaChief Executive OfficerJan 23 '24Sale0.679,5006,369863,742Jan 25 04:15 PM
Hagen Brett RChief Accounting OfficerJan 23 '24Sale0.6790160496,289Jan 25 04:15 PM
Miller EdwardGeneral CounselJan 23 '24Sale0.671,302873234,232Jan 25 04:15 PM
Hagen Brett RChief Accounting OfficerJan 04 '24Sale0.6431019897,190Jan 08 04:15 PM
Miller EdwardGeneral CounselJan 04 '24Sale0.64424271235,534Jan 08 04:15 PM
Sinha VikasSee RemarksJan 04 '24Sale0.649616141,166,788Jan 08 04:15 PM
Brainard DianaChief Executive OfficerJan 04 '24Sale0.641,6641,063873,242Jan 08 04:15 PM
Hagen Brett RChief Accounting OfficerDec 27 '23Sale0.7428,33520,83897,500Jan 02 07:36 PM
Sinha VikasSee RemarksNov 17 '23Sale1.632,4904,0611,167,749Nov 21 05:00 PM
Brainard DianaChief Executive OfficerNov 20 '23Sale1.694,3827,408874,906Nov 21 05:00 PM
Brainard DianaChief Executive OfficerNov 17 '23Sale1.632,6894,386879,288Nov 21 05:00 PM
Hagen Brett RChief Accounting OfficerNov 17 '23Sale1.63403657125,835Nov 21 05:00 PM
Hagen Brett RChief Accounting OfficerOct 19 '23Sale1.58358566126,595Oct 23 05:00 PM
Hagen Brett RChief Accounting OfficerOct 20 '23Sale1.54357550126,238Oct 23 05:00 PM
Brainard DianaChief Executive OfficerOct 19 '23Sale1.588,58113,558881,977Oct 23 05:00 PM
Sinha VikasSee RemarksOct 20 '23Sale1.541,4752,2731,170,239Oct 23 05:00 PM
Sinha VikasSee RemarksOct 19 '23Sale1.581,2321,9471,171,714Oct 23 05:00 PM
Brainard DianaChief Executive OfficerOct 03 '23Sale1.981,3252,619890,558Oct 05 05:00 PM
Sinha VikasSee RemarksOct 03 '23Sale1.987551,4921,172,946Oct 05 05:00 PM
Hagen Brett RChief Accounting OfficerOct 03 '23Sale1.98222439126,953Oct 05 05:00 PM